

## Key publications

Beffinger M, Tallón de Lara P, Tugues S, Vermeer M, Montagnolo Y, Ohs I, Cecconi V, Lucchiari G, Gagliardi A, Misljencevic N, Sutton J, Spörri R, Becher B, Gupta A, \*van den Broek M. 2018. CSF1R-dependent monocytes are required for NK-mediated control of metastasis. *J Clin Invest insight*, 3(10):e97792.

Zimmerli D, Cecconi V, Valenta T, Hausmann G, Cantù C, Restive G, Hafner J, Basler K, \*van den Broek M. 2018. WNT-ligands control initiation and progression of human papilloma-virus-driven squamous cell carcinoma. *Oncogene* <https://doi.org/10.1038/s41388-018-0244-x>.

Silina K, Soltermann A, Movahedian Attar F, Casanova R, Uckeley Z, Thut H, Isajevs S, Cheng S, Curioni-Fontecedro A, Foukas P, Levesque M, Moch H, Linē A, \*van den Broek M. 2018. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. *Cancer Res.* 78:1308-1320.

Curioni-Fontecedro A, Ickenberg C, Franzen D, Rogler G, Burger IA, \*van den Broek M. 2017. Diffuse pseudoprogression in a patient with metastatic non-small cell lung cancer treated with Nivolumab. *Annals of Oncology* 28:2040-2041. DOI: 10.1093/annonc/mdx233

Chevrier S, Levine JH, Zanotelli V, Silina K, Schulz D, Bacac M, Ries C, Ailles L, Jewett MAS, Mich H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe'er D, Bodenmiller B. 2017. An immune atlas of renal carcinoma links phenotypes to immunosuppression and clinical features. *Cell.* 169:736-749.

Bransi A, Salgado O, Beffinger M, Milo K, Silina K, Yagita H, Becher B, Knuth A, \*van den Broek M. 2015. Rational combination of immunotherapy with clinical efficacy in mice with advanced cancer. *Cancer Immunology Research* 3:1279-1288.

Surace L, Lysenko V, Fontana AO, Cecconi V, Janssen H, Bicvic A, Okoniewski M, Pruschy M, Dummer R, Neeffjes J, Knuth A, Gupta A, \*van den Broek M. 2015. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. *Immunity* 42:767-777.

Dannenmann S, Hermanns T, Bransi A, von Boehmer L, Matter C, Stevanovic S, Schraml P, Moch H, Knuth A, \*van den Broek M. 2013. Spontaneous peripheral T cell responses towards the tumor-associated antigen Cyclin D1 in patients with clear cell renal cell carcinoma. *Cancer Immunology Research* 1:288-295.

Sharma A, Bode B, Studer G, Moch H, Okoniewski M, Knuth A, von Boehmer L, \*van den Broek M. 2013. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. *Clinical Cancer Research* 19:4843-4853.

Walter A, Schäfer M, Matter C, Urosevic.Maiwald M, Belloni B, Schönewolf N, Cecconi V, Kulig P, Dummer R, Bloch W, Werner S, Beer HD, Knuth A, \*van den Broek M. 2013. Aldara activates two independent immune defense pathways. *Nature Communications* 4:1560 doi: 10.1038/ncomms2566.

Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Behnke S, Prischy M, Knuth A, \*van den Broek M. 2012. Radiotherapy promotes tumor-specific effector CD8<sup>+</sup> T cells via DC activation. *J. Immunol.* 189:558-566.

Schildknecht A, Brauer S, Brenner C, Lahl K, Schild HJ, Sparwasser T, Probst HC, \*van den Broek M. FoxP3<sup>+</sup> regulatory T cells essentially contribute to peripheral CD8<sup>+</sup> T cell tolerance induced by steady-state dendritic cells. 2010. *Proc. Natl. Acad. Sci. USA* 107:199-203.

Keller AM, Schildknecht A, Xiao Y, \*van den Broek M, Borst J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8<sup>+</sup> T cell tolerance and permits effective immunity. 2008. *Immunity* 29:1-13.

Probst HC, McCoy K, Okazaki T, Honjo T, \*van den Broek M. 2005. Resting dendritic cells induce peripheral CD8<sup>+</sup> T cell tolerance in vivo through PD-1 and CTLA-4. *Nature Immunology* 6:280-286.